Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity

More on GLP-1 and incretin signalling

• Nutrient deficiencies raise metabolic risk in obesity

  Nutrients · 4 Oct 2026

• GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026